Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif.
| Revenue (Most Recent Fiscal Year) | $46.74M |
| Net Income (Most Recent Fiscal Year) | $-114.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.10 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -159.09% |
| Net Margin (Trailing 12 Months) | -159.10% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -93.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.14 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 5.01 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.18 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.24 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.83 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 243.31M |
| Free Float | 224.70M |
| Market Capitalization | $60.46M |
| Average Volume (Last 20 Days) | 1.17M |
| Beta (Past 60 Months) | 1.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.65% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |